BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 22120712)

  • 1. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
    Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
    Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MdmX inhibits ARF mediated Mdm2 sumoylation.
    Ghosh M; Weghorst K; Berberich SJ
    Cell Cycle; 2005 Apr; 4(4):604-8. PubMed ID: 15876864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation.
    Jackson MW; Lindstrom MS; Berberich SJ
    J Biol Chem; 2001 Jul; 276(27):25336-41. PubMed ID: 11297540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
    de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
    J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of p53: a collaboration between Mdm2 and Mdmx.
    Pei D; Zhang Y; Zheng J
    Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.
    Jin Y; Zeng SX; Sun XX; Lee H; Blattner C; Xiao Z; Lu H
    Mol Cell Biol; 2008 Feb; 28(4):1218-29. PubMed ID: 18086887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
    Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
    Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
    EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of MDMX by sumoylation.
    Pan Y; Chen J
    Biochem Biophys Res Commun; 2005 Jul; 332(3):702-9. PubMed ID: 15907800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X
    Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.